Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER director

This article was originally published in The Tan Sheet

Executive Summary

Janet Woodcock is named director of the Center for Drug Evaluation and Research, where she has served as acting director for six months, the agency says March 10. She previously served as FDA's chief medical officer and as a deputy commissioner. An internist and rheumatologist, Woodcock has held other leadership positions at FDA, including Office of Therapeutics Research and Review director and Center for Biologics Evaluation and Research acting deputy director as well as previous service as CDER director (1"The Tan Sheet" Dec. 10, 2007, In Brief). The Safety First program CDER launched this month is one initiative Woodcock has led since becoming acting CDER director (2"The Tan Sheet" March 3, 2008, p. 9). She also led the agency's launch of the Critical Path Initiative, designed to bridge the gap between basic scientific research and the medical product development process...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel